Details for Patent: 9,492,410
✉ Email this page to a colleague
Title: | Methods for treatment of Parkinson's disease |
Abstract: | New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists. |
Inventor(s): | Fariello; Ruggero (Luino, IT), Cattaneo; Carlo (Milan, IT), Salvati; Patricia (Arese, IT), Benatti; Luca (S. Maurizio al Lambro, IT) |
Assignee: | NEWRON PHARMACEUTICALS S.P.A. (Bresso, IT) |
Filing Date: | Nov 04, 2014 |
Application Number: | 14/532,925 |
Claims: | 1. A method of treating secondary and psychosocial symptoms of idiopathic Parkinson's disease comprising: administering a therapeutically effective stable dose of a single dopamine agonist; and concurrently administering a therapeutically effective amount of safinamide, or a pharmaceutically acceptable salt thereof, on an oral daily dosage schedule. 2. The method according to claim 1, wherein said secondary and psychosocial symptoms are selected from bradyphrenia, constipation, dementia, dysphagia, hyperhidrosis, hypersalivation, hypophonia, incontinence, micrographia, anxiety, depression, isolation and seborrhea. 3. The method according to claim 1, wherein safinamide, or a pharmaceutically acceptable salt thereof, is administered for at least 12 weeks. 4. The method according to claim 1, wherein safinamide, or a pharmaceutically acceptable salt thereof, is administered once daily. 5. The method according to claim 1, wherein safinamide is administered as the methanesulfonate salt. 6. The method according to claim 1, wherein the single dopamine agonist is selected from the group consisting of ropinirole, pramiprexole, rotigotine, bromocriptine, cabergoline, lisuride, pergolide, apomorphine, sumanirole, talipexole and dihydroergocriptine. 7. A method of limiting adverse events in a patient with idiopathic Parkinson's disease comprising: administering a therapeutically effective stable dose of a single dopamine agonist; and concurrently administering a therapeutically effective amount of safinamide, or a pharmaceutically acceptable salt thereof, on an oral daily dosage schedule. 8. The method according to claim 7, wherein safinamide, or a pharmaceutically acceptable salt thereof, is administered for at least 12 weeks. 9. The method according to claim 7, wherein safinamide, or a pharmaceutically acceptable salt thereof, is administered once daily. 10. The method according to claim 7, wherein safinamide is administered as the methanesulfonate salt. 11. The method according to claim 7, wherein the single dopamine agonist is selected from the group consisting of ropinirole, pramiprexole, rotigotine, bromocriptine, cabergoline, lisuride, pergolide, apomorphine, sumanirole, talipexole and dihydroergocriptine. 12. A method of treating idiopathic Parkinson's disease comprising: administering a therapeutically effective stable dose of a single dopamine agonist selected from the group consisting of bromocriptine, cabergoline, lisuride, pergolide, apomorphine, sumanirole, talipexole and dihydroergocriptine; and concurrently administering a therapeutically effective amount of safinamide, or a pharmaceutically acceptable salt thereof, on an oral daily dosage schedule. 13. The method according to claim 12, wherein safinamide, or a pharmaceutically acceptable salt thereof, is administered for at least 12 weeks. 14. The method according to claim 12, wherein safinamide, or a pharmaceutically acceptable salt thereof, is administered once daily. 15. The method according to claim 12, wherein safinamide is administered as the methanesulfonate salt. 16. The method according to claim 7, wherein the adverse events are selected from abdominal pain, abdominal pain upper, vomiting, diarrhea, somnolence, and headache. |